Jan 15, 2020 / 06:30PM GMT
Cory William Kasimov - JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst
All right. Good morning, everyone. My name is Cory Kasimov. I'm a senior biotech analyst at JPMorgan. And it's my pleasure to introduce our next company, Editas. Here to present for Editas is the company's CEO, Cindy Collins. And please note that following Cindy's presentation, there's a breakout across the hall in the Borgia Room.
So with that, I turn it over to Cindy.
Cynthia L. Collins - Editas Medicine, Inc. - CEO, President & Director
Thank you, Cory, and thanks for the invitation to speak here today. Pushing the boundaries of medicine entails risk as well as great promise. This slide tells you all about the risk. At Editas, we strive to make differentiated, transformational medicines for diseases of high unmet need. To accomplish this objective, we are pursuing 2 strategic pillars, in vivo CRISPR medicine and engineered cell medicines. In our in vivo CRISPR medicine portfolio, we are able to leverage AAV-mediating editing with our proprietary
Editas Medicine Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers